ImmunityBio is a clinical-stage biotechnology company developing therapies and vaccines that complement, harness, and amplify the immune system to defeat cancers and infectious diseases. Co.'s platforms include: antibody cytokine fusion proteins, which include Anktiva™, a class of biopharmaceuticals that improve the therapeutic potential of cytokines, and promote lymphocyte infiltration at a site of disease, improving immune response; and DNA, RNA, and recombinant protein vaccine technologies, which are for infectious diseases to target key viruses, including coronavirus, and for oncology to deliver tumor-associated antigens, and neoepitopes (expressed only by cancer cells). We show 13 historical shares outstanding datapoints in our IBRX shares outstanding history coverage, used to compute IBRX market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing IBRX market cap history over the course of time is important for investors
interested in comparing IBRX's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of IBRX versus a peer is one thing; comparing
IBRX market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like IBRX can fluctuate over the course of history.
With this page we aim to empower investors researching IBRX by allowing them to research the IBRX market cap history. |
Free IBRX Email Alerts:
Video: The Importance of Market Cap
